Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Cambridge Cognition Holdings ( (GB:COG) ) has provided an update.
Cambridge Cognition Holdings, a leader in brain health software, has announced the appointment of Jonathan Kempster as an independent Non-Executive Director. Kempster brings over 20 years of experience as a public company director and significant financial expertise, which is expected to strengthen the company’s governance and investor relations, aiding its business growth and development.
More about Cambridge Cognition Holdings
Cambridge Cognition is a brain health software group specializing in digital health products that advance brain health research and treatment. The company offers core products such as CANTAB® assessments for cognitive function, a flexible eCOA platform, rater training services, and quality assurance tools. These products aim to improve clinical trial outcomes, enable early patient identification, and enhance global healthcare and pharmaceutical efficiency.
YTD Price Performance: 21.33%
Average Trading Volume: 63,310
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £19.05M
For detailed information about COG stock, go to TipRanks’ Stock Analysis page.
